Small Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble "oat cells" under the microscope. Small cell carcinoma most often affects the lungs. Clinically, this is often a rapidly growing cancer that spreads to distant sites early. 
Small cell carcinomas most frequently harbor alterations in TP53, RB1, KMT2D, CREBBP, and PTEN .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, RB1 Mutation, and TP53 Exon 5 Mutation are the most common alterations in small cell carcinoma .
There are 6 clinical trials for small cell carcinoma, of which 5 are open and 1 is completed or closed. Of the trials that contain small cell carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open).
DLL3 is the most frequent gene inclusion criterion for small cell carcinoma clinical trials .
Berzosertib, topotecan, and bi 764532 are the most common interventions in small cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.